CClinicalTrials.gg
Sign In
Not yet recruitingNCT05706974Updated Mar 6, 2023

Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials

An observational study in Bile Duct Cancer, sponsored by Power Life Sciences Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical trials, both positive and negative.

The goal is to identify the obstacles and challenges that prevent participation in bile duct cancer clinical trials, as well as the reasons for withdrawal or discontinuation.

The insights gained from this study will ultimately benefit those with bile duct cancer who may be invited to participate in medical research in the years to come.

02

Conditions studied

  • Bile Duct Cancer

Keywords

  • bile duct
  • bile duct cancer
03

In context

Bile Duct Neoplasms

217 studies on the registry are indexed under Bile Duct Neoplasms; 43 are open to participants now.

This study's planned enrollment of 500 is above the median of 169 across 40 observational studies indexed under Bile Duct Neoplasms.

Browse Bile Duct Neoplasms studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 108 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Bile duct cancer patients who are actively considering participating in an observational medical study, but have not yet completed enrollment and randomization.

Inclusion criteria

  • Age ≥ 18 years
  • Signed written informed consent
  • Patient has been diagnosed with bile duct cancer

Exclusion criteria

Exclusion Criteria:

  • Woman pregnant or susceptible to the being
  • Inability to perform regular electronic reporting
  • Inclusion in another investigational clinical trial
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of bile duct cancer patients who decide to enroll in a clinical study

    Time frame: 3 months

  2. Rate of bile duct cancer patients who remain in a clinical study to completion

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Norton RA, Foster EA. Bile duct cancer. CA Cancer J Clin. 1990 Jul-Aug;40(4):225-33. doi: 10.3322/canjclin.40.4.225. PubMed 2114201 ↗
  • Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M; Bile Duct Cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018 Feb;105(3):192-202. doi: 10.1002/bjs.10776. PubMed 29405274 ↗
  • Xiang YJ, Sun JX, Wu JY, Wang K, Feng JK, Wei YG, Zhou JY, Zhang ZB, Zhang YQ, Qin YY, Yan ML, Cheng SQ. Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. HPB (Oxford). 2022 Oct;24(10):1703-1710. doi: 10.1016/j.hpb.2022.04.007. Epub 2022 Apr 22. PubMed 35523655 ↗

Study documents

  • Informed consent form · Jan 20, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05706974
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Feb 2024 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Mar 6, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
4159004227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Bile Duct Neoplasms→

Other studies from this sponsor

Power Life Sciences Inc.

Start the discussion